Tesofensine

Origin and a Note on Classification

Tesofensine (development code NS2330) is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor originally developed by the Danish pharmaceutical company NeuroSearch in the 1990s as a candidate for Alzheimer's disease and Parkinson's disease. Its presence in a peptide library is a reflection of how the weight-loss marketplace has blurred categories: tesofensine is co-marketed alongside GLP-1 peptides and functions as a competing obesity therapy, so understanding it is useful context for anyone comparing options.

After disappointing results in the Alzheimer's and Parkinson's indications, NeuroSearch pivoted tesofensine to obesity. Phase 2 trials in the late 2000s produced the results that made the compound notable, but the pivotal Phase 3 program intended for European approval was shelved, and the compound's commercial trajectory has been unusual ever since.

Mechanism of Action

Tesofensine inhibits the reuptake of dopamine, norepinephrine, and serotonin in the central nervous system. The combined monoamine elevation is thought to suppress appetite through multiple central pathways:

• Hypothalamic appetite centers. Increased noradrenergic and dopaminergic tone reduces hunger drive.
• Reward and food-seeking. Dopaminergic activity in mesolimbic circuits reduces the reward value of palatable food.
• Energy expenditure. Modest increases in resting metabolic rate have been reported, likely sympathomimetic.

This mechanism places tesofensine in the same pharmacological family as phentermine, sibutramine (withdrawn in 2010 over cardiovascular safety), and bupropion — rather than the GLP-1 class represented by semaglutide and tirzepatide.

Clinical Evidence

The TIPO-1 trial (Astrup et al., The Lancet 2008) was the landmark study: a 24-week Phase 2 trial in Danish obese adults reported mean weight reductions of 12.8 kg on tesofensine 1.0 mg, versus roughly 2.2 kg on placebo — effect sizes that at the time were larger than any approved obesity drug. Subsequent 48-week extension data maintained the weight loss.

The problem was the side effect profile. Dose-dependent increases in heart rate, blood pressure elevations, dry mouth, insomnia, and mood effects were reported. NeuroSearch's planned Phase 3 program in Scandinavia did not advance to registration. The drug was then licensed to the Mexican company Saniona, which has since marketed a formulation under the trade name Tesomet (tesofensine combined with low-dose metoprolol to blunt cardiovascular effects) and pursued rare-disease indications including hypothalamic obesity and Prader–Willi syndrome in smaller trials.

As of early 2026, tesofensine is approved for obesity in Mexico and a small number of Latin American markets but has not achieved FDA or EMA approval.

Safety Profile

The principal concerns are cardiovascular and psychiatric:

• Heart rate and blood pressure elevations. Dose-dependent; the reason for the metoprolol combination in Tesomet.
• Insomnia, anxiety, irritability. Reflect the monoaminergic stimulant profile.
• Dry mouth and constipation. Common.
• Abuse/dependence potential. Dopamine reuptake inhibitors raise theoretical concerns, though clinical abuse signals have been modest.

The sibutramine precedent — a serotonin-norepinephrine reuptake inhibitor withdrawn after the SCOUT trial showed cardiovascular harm — is the main reason Western regulators have been cautious about tesofensine.

Practical Considerations

Where approved, tesofensine is an oral tablet, typically 0.5–1.0 mg once daily. Because it is a scheduled stimulant-class compound, access in Latin American markets is by prescription. In the U.S. and most of Europe it is not legally available. Some compounding pharmacies have marketed tesofensine domestically in gray-market fashion — this practice sits outside FDA-sanctioned compounding and carries both regulatory and safety risk.

The Bottom Line

Tesofensine is a small molecule with genuinely large Phase 2 weight-loss effects, trapped for over 15 years between a Scandinavian Phase 3 program that was abandoned and a Mexican commercial existence that has not translated to global approval. For someone comparing it to GLP-1 peptides, the central tradeoff is efficacy that is competitive with older GLP-1 agents, at the cost of a cardiovascular/psychiatric side effect profile that the newer GLP-1 class does not share. Most readers in jurisdictions where semaglutide or tirzepatide are accessible will find the risk-benefit of those alternatives considerably cleaner.